Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Post by KayDayon Jan 18, 2014 2:24pm
427 Views
Post# 22107653

Reunion

ReunionWell it looks like the gang is almost all here... all we need is RS to tell us we are all fools and a crazy person to stalk Digger69.
For those new to the stock.... SSS went higher than $5.00 on many patents but only one major trial that dealt with Stroke.  The collapse came not because the drug didn't work but because the trial had a flaw that was discovered too late.  The drug worked with the brain to fix damage like steroids work with the muscle to make it grow.  It was found out after the collapse of the stock and release of the results that not all trial centers were giving occupational therapy to its patients.  That is like taking a steroid and not lifting weights.
There was a cleaning of the house after that was realized and a major shareholder pulled together a dream team to turn this company around.  Allan was the man behind YM Biosciences... just look at that record.
As to what they are doing now... they are taking this company to a level that is mind blowing.  I can assure you I was not happy with the reverse split because that rarely works out well... but in this case... they have since started trading in the US and raised 33 million dollars.  With pre-clinical trials in acute myeloid leukaemia and interstitial cystitis, and worldwide rights to a series of prostate stem cell assets... they are looking really good.  I am sure others will elaborate more. 
Bullboard Posts